Five‐day continuous infusion of 5‐fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma

Herbert A. Hartman, Anne Kessinger, Henry M. Lemon, John F. Foley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In a retrospective study, 58 patients with advanced colorectal carcinoma received one or more 5‐day infusions of 5‐FU at 20 mg/kg per 24 hours followed by weekly IV 5‐FU at 15 mg/kg. In 36 patients who received the infusion as first treatment (Group A), the response rate was 23% with a median duration of response of 8.0 months. No improvement in survival was noted. In 22 patients treated with the infusion after relapse on weekly 5‐FU (Group B), the response rate was 10.5% with a median duration of response of 4.5 months. Stable disease for 3‐6 months was seen in 21%. Survival in Group B was improved when compared with a similar group of patients treated by weekly 5‐FU without infusion (Group CB), but statistical significance was not obtained. Twenty percent of patients were alive two years after relapsing on weekly 5‐FU when given the five‐day infusion of 5‐FU and re‐initiated on weekly 5‐FU. Toxicity t o the five‐day infusion of 5‐FU was minimal. Three of 69 (4.3%) infusions were not completed because of toxicity. A separate review of procarbazine indicated that it was minimally active in colorectal carcinoma. Other patients with gastric and pancreatic carcinoma were reviewed but no statistical significance for 5‐FU infusion was seen for survival. A five day continuous infusion of 5‐FU is recommended for colorectal cancer patients who relapse on weekly 5‐FU therapy. Further study of the infusion in combination with other chemotherapy is warranted.

Original languageEnglish (US)
Pages (from-to)227-238
Number of pages12
JournalJournal of Surgical Oncology
Volume11
Issue number3
DOIs
StatePublished - 1979

Fingerprint

Fluorouracil
Stomach
Adenocarcinoma
Colorectal Neoplasms
Survival
Procarbazine
Recurrence
Retrospective Studies
Drug Therapy

Keywords

  • 5‐FU infusion
  • gastrointestinal cancer
  • response reinductio

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Five‐day continuous infusion of 5‐fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma. / Hartman, Herbert A.; Kessinger, Anne; Lemon, Henry M.; Foley, John F.

In: Journal of Surgical Oncology, Vol. 11, No. 3, 1979, p. 227-238.

Research output: Contribution to journalArticle

Hartman, Herbert A. ; Kessinger, Anne ; Lemon, Henry M. ; Foley, John F. / Five‐day continuous infusion of 5‐fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma. In: Journal of Surgical Oncology. 1979 ; Vol. 11, No. 3. pp. 227-238.
@article{ca6a3f04af99472984b1527d450f0789,
title = "Five‐day continuous infusion of 5‐fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma",
abstract = "In a retrospective study, 58 patients with advanced colorectal carcinoma received one or more 5‐day infusions of 5‐FU at 20 mg/kg per 24 hours followed by weekly IV 5‐FU at 15 mg/kg. In 36 patients who received the infusion as first treatment (Group A), the response rate was 23{\%} with a median duration of response of 8.0 months. No improvement in survival was noted. In 22 patients treated with the infusion after relapse on weekly 5‐FU (Group B), the response rate was 10.5{\%} with a median duration of response of 4.5 months. Stable disease for 3‐6 months was seen in 21{\%}. Survival in Group B was improved when compared with a similar group of patients treated by weekly 5‐FU without infusion (Group CB), but statistical significance was not obtained. Twenty percent of patients were alive two years after relapsing on weekly 5‐FU when given the five‐day infusion of 5‐FU and re‐initiated on weekly 5‐FU. Toxicity t o the five‐day infusion of 5‐FU was minimal. Three of 69 (4.3{\%}) infusions were not completed because of toxicity. A separate review of procarbazine indicated that it was minimally active in colorectal carcinoma. Other patients with gastric and pancreatic carcinoma were reviewed but no statistical significance for 5‐FU infusion was seen for survival. A five day continuous infusion of 5‐FU is recommended for colorectal cancer patients who relapse on weekly 5‐FU therapy. Further study of the infusion in combination with other chemotherapy is warranted.",
keywords = "5‐FU infusion, gastrointestinal cancer, response reinductio",
author = "Hartman, {Herbert A.} and Anne Kessinger and Lemon, {Henry M.} and Foley, {John F.}",
year = "1979",
doi = "10.1002/jso.2930110307",
language = "English (US)",
volume = "11",
pages = "227--238",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Five‐day continuous infusion of 5‐fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma

AU - Hartman, Herbert A.

AU - Kessinger, Anne

AU - Lemon, Henry M.

AU - Foley, John F.

PY - 1979

Y1 - 1979

N2 - In a retrospective study, 58 patients with advanced colorectal carcinoma received one or more 5‐day infusions of 5‐FU at 20 mg/kg per 24 hours followed by weekly IV 5‐FU at 15 mg/kg. In 36 patients who received the infusion as first treatment (Group A), the response rate was 23% with a median duration of response of 8.0 months. No improvement in survival was noted. In 22 patients treated with the infusion after relapse on weekly 5‐FU (Group B), the response rate was 10.5% with a median duration of response of 4.5 months. Stable disease for 3‐6 months was seen in 21%. Survival in Group B was improved when compared with a similar group of patients treated by weekly 5‐FU without infusion (Group CB), but statistical significance was not obtained. Twenty percent of patients were alive two years after relapsing on weekly 5‐FU when given the five‐day infusion of 5‐FU and re‐initiated on weekly 5‐FU. Toxicity t o the five‐day infusion of 5‐FU was minimal. Three of 69 (4.3%) infusions were not completed because of toxicity. A separate review of procarbazine indicated that it was minimally active in colorectal carcinoma. Other patients with gastric and pancreatic carcinoma were reviewed but no statistical significance for 5‐FU infusion was seen for survival. A five day continuous infusion of 5‐FU is recommended for colorectal cancer patients who relapse on weekly 5‐FU therapy. Further study of the infusion in combination with other chemotherapy is warranted.

AB - In a retrospective study, 58 patients with advanced colorectal carcinoma received one or more 5‐day infusions of 5‐FU at 20 mg/kg per 24 hours followed by weekly IV 5‐FU at 15 mg/kg. In 36 patients who received the infusion as first treatment (Group A), the response rate was 23% with a median duration of response of 8.0 months. No improvement in survival was noted. In 22 patients treated with the infusion after relapse on weekly 5‐FU (Group B), the response rate was 10.5% with a median duration of response of 4.5 months. Stable disease for 3‐6 months was seen in 21%. Survival in Group B was improved when compared with a similar group of patients treated by weekly 5‐FU without infusion (Group CB), but statistical significance was not obtained. Twenty percent of patients were alive two years after relapsing on weekly 5‐FU when given the five‐day infusion of 5‐FU and re‐initiated on weekly 5‐FU. Toxicity t o the five‐day infusion of 5‐FU was minimal. Three of 69 (4.3%) infusions were not completed because of toxicity. A separate review of procarbazine indicated that it was minimally active in colorectal carcinoma. Other patients with gastric and pancreatic carcinoma were reviewed but no statistical significance for 5‐FU infusion was seen for survival. A five day continuous infusion of 5‐FU is recommended for colorectal cancer patients who relapse on weekly 5‐FU therapy. Further study of the infusion in combination with other chemotherapy is warranted.

KW - 5‐FU infusion

KW - gastrointestinal cancer

KW - response reinductio

UR - http://www.scopus.com/inward/record.url?scp=0018746494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018746494&partnerID=8YFLogxK

U2 - 10.1002/jso.2930110307

DO - 10.1002/jso.2930110307

M3 - Article

C2 - 459516

AN - SCOPUS:0018746494

VL - 11

SP - 227

EP - 238

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -